key: cord-0723124-fzntgmis
authors: Flores-Pérez, Patricia; Gerig, Nathalia; Isabel Cabrera-López, Mª; de Unzueta-Roch, José L; Rosal, Teresa del; Calvo, Cristina
title: Acute Bronchiolitis During The Covid-19 Pandemic
date: 2021-06-26
journal: Enferm Infecc Microbiol Clin
DOI: 10.1016/j.eimc.2021.06.012
sha: 92820f4f047178d25c0f8a37ec5551a1fe000426
doc_id: 723124
cord_uid: fzntgmis

Introduction: The autumn and winter bronchiolitis epidemics have virtually disappeared in the first year of the COVID-19 pandemic. Our objectives were characterise bronchiolitis during fourth quarter of 2020 and the role played by SARS-CoV-2. Methods: Prospective multi-centre study performed in Madrid (Spain) between October and December 2020 including all children admitted with acute bronchiolitis. Clinical data were collected and multiplex PCR for respiratory viruses were performed. Results: Thirty-three patients were hospitalised with bronchiolitis during the study period: 28 corresponded to rhinovirus (RV), 4 to SARS-CoV-2, and 1 had both types of infection. SAR-CoV-2 bronchiolitis were comparable to RV bronchiolitis except for a shorter hospital stay. A significant decrease in the admission rate for bronchiolitis was found and no RSV was isolated. Conclusion: SARS-CoV-2 infection rarely causes acute bronchiolitis and it is not associated with a severe clinical course. During COVID-19 pandemic period there was a marked decrease in bronchiolitis cases.

Worldwide, the autumn and winter RSV epidemics have virtually disappeared, and in some countries in the Southern Hemisphere like South Africa or Australia, the RSV season has moved to spring, marking an unprecedented phenomenon 2 . The incidence of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children is relatively low, and the disease causes lower symptom severity compared to adults. There is little information about the role of SARS-CoV-2 in bronchiolitis, although experimental studies performed in ferrets have shown lung lesions compatible with bronchiolitis 3 . In addition, other human coronaviruses (HCoV) have been detected in up to 5% infants with bronchiolitis, with OC43 and 229E being associated with greater disease severity 4 .

We aimed to describe the epidemiology of bronchiolitis requiring hospitalisation during the fourth quarter of 2020 and characterise bronchiolitis associated with SARS-CoV-2 infection. Additionally, we compare the number of cases during the same period in 2019. Patients with a severe underlying disease such as haematological cancer, immunodeficiency, or chronic pulmonary disease (e.g., cystic fibrosis, obliterative bronchiolitis, interstitial disease) and those undergoing chronic immunosuppressive treatment were excluded.

Additionally, we reviewed the number of cases and the proportion of RSV bronchiolitis recorded during the same period in 2019.

Qualitative data were expressed as absolute and relative frequencies and quantitative data as median and interquartile range (IQR). Categorical variables were compared using the chi-square and Fisher's exact test, and continuous variables were analysed with non-parametric tests as appropriate. A two-tailed p value <0.05 was considered statistically significant. All analyses were performed using the Statistical Package for the Social Sciences, version 21.0 (IBM Corp., CA, USA).

The study was approved by the ethics committee of both hospitals and parents signed informed consent. We found a dramatic decrease in the total number of paediatric admissions between 2019 and 2020 for the same seasonal period (833 vs 435 children) and in the number of admissions due to bronchiolitis (271 vs 33 children), a difference that was statistically significant (32.53% vs 7.59%, p<0.001). In 2019, most bronchiolitis cases were caused by RSV (241/271 bronchiolitis), while in 2020 there were no cases.

Our results confirm the substantial change in the epidemiology of viral respiratory infections caused by the COVID-19 pandemic. The yearly wave of bronchiolitis admissions was virtually nonexistent, as in other countries [5] [6] [7] . The annual RSV epidemic has not taken place yet, and it is unclear whether it will start during the next few months. In Australia, after the reduction of COVID-19 non-pharmacological interventions and the arrival of summer, an unusually delayed and steeper `summer bronchiolitis and RSV peak´ has been seen in certain regions, with an older median age and higher total numbers compared to the usual winter peaks 8 . We might be pushing the 'RSV curve' forward and may not be able to stop this trend when we arrive at the exponential phase.

Due to the small number of patients included, we lack sufficient data to reach precise conclusions about SARS-CoV-2 bronchiolitis and how it differs from other viral infections. In our sample, infection with SARS-CoV-2 was not associated with increased disease severity. SARS-CoV-2 and RV bronchiolitis seem to have a similar clinical course although patients with SARS-CoV-2 bronchiolitis had shorter hospital stay and did not require advanced support treatment or ICU admission. This could be due, at least partially, to none of the COVID-19 patients having underlying diseases and only one being prescribed parenteral antibiotics because of suspected bacterial superinfection.

Regarding our case with coinfection due to SARS-CoV-2 and RV, it is known that coinfection is possible but might occur infrequently; not only the elderly or people with systemic diseases are at risk from this coinfection, but healthy children are also 9 , which could impact the treatment and prognosis of the disease.

The number of bronchiolitis admissions in both centres for the current autumn-winter season has been much lower than predicted based on previous years. 

Viral bronchiolitis. The Lancet

COVID-19 public health measures and respiratory syncytial virus

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

A 14-year Prospective Study of Human Coronavirus Infections in Hospitalized Children: Comparison With Other Respiratory Viruses

Early Impact of Social Distancing in Response to Coronavirus Disease 2019 on Hospitalizations for Acute Bronchiolitis in Infants in Brazil

Bronchiolitis in COVID-19 times: a nearly absent disease?

Trends in US Pediatric Hospital Admissions in 2020 Compared With the Decade Before the COVID-19 Pandemic

Public Health Measures on Detections of Influenza and Respiratory Syncytial Virus in Children During the 2020 Australian Winter

The microbial coinfection in COVID-19

Rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France

Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology

How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1